The ASO targeting metadherin (MTDH), a gene can promote PD-L1 expression, was able to improve anti-PD-1 mAb therapy in hepatocellular cancer (HCC) [38]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.